53 results
-
List item
Human medicine European public assessment report (EPAR): Telzir
fosamprenavir calcium, HIV Infections
Date of authorisation: 12/07/2004, Revision: 47, Authorised, Last updated: 11/04/2022Telzir Blood-Borne Infections Communicable … rised fosamprenavir Overview Telzir is an antiviral medicine … deficiency syndrome (AIDS). Telzir is used in combination with … -
List item
Press release: Updated advice on body fat changes and lactic acidosis with HIV medicines
CHMP, Last updated: 23/10/2015Rezolsta, Stribild, Sustiva, Telzir, Triumeq, Trizivir, Truvada … Rezolsta, Stribild, Sustiva, Telzir, Triumeq, Trizivir, Truvada … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2016
CHMP, Last updated: 26/02/2016Name of medicine Telzir INN fosamprenavir Marketing-authorisation … -
List item
National expert: Veronique Tonnay, National Agency For The Safety Of Medicine And Health Products (updated)
- Declaration of interests - 80.59 KB | PDF
- Curriculum Vitae - 16.5 KB | PDF
Trizivir) Retrovir, Epivir Combivir Telzir Zeffix HIV treatment 2.2 … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 October 2015
CHMP, Last updated: 23/10/2015Sustiva: EPAR Tecfidera: EPAR Telzir: EPAR Trizivir: EPAR Truvada … -
List item
Human medicine European public assessment report (EPAR): Celsentri
maraviroc, HIV Infections
Date of authorisation: 18/09/2007, Revision: 27, Authorised, Last updated: 18/01/2022 -
List item
Human medicine European public assessment report (EPAR): Reyataz
atazanavir (as sulfate), HIV Infections
Date of authorisation: 01/03/2004, Revision: 52, Authorised, Last updated: 18/02/2022 -
List item
Human medicine European public assessment report (EPAR): Agenerase
amprenavir, HIV Infections
Date of authorisation: 20/10/2000, Revision: 18, Withdrawn, Last updated: 21/06/2011 -
List item
Human medicine European public assessment report (EPAR): Viracept
nelfinavir, HIV Infections
Date of authorisation: 22/01/1998, Revision: 25, Withdrawn, Last updated: 10/06/2014 -
List item
Opinion on medicine for use outside EU: Lamivudine ViiV
lamivudine, HIV Infections, ATC code: J05AF05 Opinion number: H/W/673, Withdrawn opinion Opinion date: 17/11/2005, Last updated: 05/07/2018 -
List item
Orphan designation: hydrocortisone for: Treatment of adrenal insufficiency
Date of designation: 22/05/2006, Expired, Last updated: 25/11/2021 -
List item
Opinion on medicine for use outside EU: Lamivudine / Zidovudine ViiV (previously Lamivudine / Zidovudine GSK)
lamivudine, zidovudine, HIV Infections, ATC code: J05AR01 Opinion number: H/W/672, Withdrawn opinion Opinion date: 17/11/2005, Last updated: 05/07/2018 -
List item
Orphan designation: hydrocortisone for: Treatment of congenital adrenal hyperplasia
Date of designation: 27/07/2005, Positive, Last updated: 14/06/2021 -
List item
Orphan designation: dexamethasone for: Treatment of multiple myeloma
Date of designation: 09/06/2010, Withdrawn, Last updated: 12/02/2018kezelése Italian Desametasone (compressa da 40 mg) Trattamento del … -
List item
Committee for Medicinal Products for Human Use (CHMP): 9-12 November 2020
Virtual meeting, from 09/11/2020 to 12/11/2020, Last updated: 07/01/2021 -
List item
PRAC: Agendas, minutes and highlights
Last updated: 04/07/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 June 2021
European Medicines Agency, Amsterdam, the Netherlands, from 07/06/2021 to 10/06/2021, Last updated: 07/06/2021 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 18/08/2022 -
List item
Download medicine data
Last updated: 02/12/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 26-29 November 2012
European Medicines Agency, London, UK, from 26/11/2012 to 29/11/2012, Last updated: 26/11/2012 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 October 2015
European Medicines Agency, London, UK, from 19/10/2015 to 22/10/2015, Last updated: 03/01/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 10-13 June 2014
European Medicines Agency, London, UK, from 10/06/2014 to 13/06/2014, Last updated: 13/08/2013 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 July 2014
European Medicines Agency, London, UK, from 07/07/2014 to 10/07/2014, Last updated: 13/08/2013 -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use,16-19 February 2009
CHMP, Last updated: 19/02/2009removing a contraindication for Telzir, from Glaxo Group Ltd, saying … treated with the medicine. Telzir in combination with low … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 5-8 October 2015
European Medicines Agency, London, UK, from 05/10/2015 to 08/10/2015, Last updated: 13/03/2014